我武生物：屋尘螨膜剂 I 期临床试验总结报告完成

Core Viewpoint - The company has completed a Phase I clinical trial for its "house dust mite film agent," demonstrating good safety and tolerability in adult patients with dust mite allergic rhinitis in China [1] Group 1: Clinical Trial Results - The clinical trial was randomized, double-blind, placebo-controlled, and involved dose escalation [1] - Safety analysis indicated that all maintenance dose groups (150BU-2700BU) showed good safety, with adverse events classified as grade 1-2, and no serious adverse events or events leading to withdrawal were reported [1] Group 2: Immune Response Indication - Exploratory analysis revealed an upward trend in specific IgE and IgG4 levels related to house dust mites in the treatment groups compared to baseline, suggesting that continuous administration for 28 days may have induced an immune response [1]